Leadiant gets Priority Review voucher

FDA issued a Priority Review voucher to Leadiant Biosciences Inc. The voucher was issued after FDA approved Leadiant's Revcovi elapegademase-lvlr (EZN-2279) to treat pediatric and adult patients with adenosine deaminase severe combined immunodeficiency (see "FDA Approves Leadiant Therapy for ADA-SCID").

The pegylated recombinant adenosine deaminase enzyme replacement therapy has Orphan Drug and Fast Track status from FDA...